A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

NCT02576431 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

215

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors Harboring NTRK Fusion

Interventions

DRUG: BAY2757556 (Larotrectinib, Vitrakvi)

Sponsor

Bayer